ACCESS Newswire

Wuhan General Group, Inc.

21.7.2021 15:18:14 CEST | ACCESS Newswire | Press release

Share
M2Bio Sciences Food and Beverage Launches CBD Sachets

CAPE TOWN, SA / ACCESSWIRE / July 21, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:

M2Bio Sciences Food & Beverage is pleased to announce the launch of the M2Bio 10mg CBD Dissolvable Powder Sachets. The sachets are the latest innovation from the Company's M2Bio brand portfolio of products, offering adults the opportunity to enjoy CBD their way. The sachet contains high-quality CBD isolate sourced from Oregon, USA. Each sachet contains 10mg of water-soluble CBD.

The convenient pre-packaged powder format makes it easy to mix the sachets contents into any beverage quickly and easily. The versatility of the product enables the consumer to enjoy premium CBD in a wide variety of settings and on any occasion of their choosing.

"The M2Bio CBD Sachets showcase the creativity, focus, and expertise of M2Bio's product development team and reinforces our company commitment to growth through innovation. Consumers who have tried our Medspresso™ CBD beverage range also enquired about CBD in its raw form. Offering the customers, the water-soluble CBD powder, allows them the flexibility to infuse it with other foods and beverages as well. Ultimately, we want to get as many people to experience the health benefits of CBD and this is a step in the right direction. We have developed a process and product that blend science and individual tastes to help adults explore new, personal CBD experiences," says Michael Sachar, CEO of M2Bio Sciences Food and Beverage.

Key features of the M2Bio CBD Sachets include the following:

  • Customizable: Can easily be added to almost any beverage, transforming it into a CBD-infused drink in a matter of seconds.
  • Rapid: M2Bio Sachets dissolve rapidly into beverages for a quick, straightforward CBD experience. In addition, the nano-emulsion formula provides improved absorption compared to traditional edibles and other delivery mechanisms.
  • Discreet: M2Bio Sachets are odorless and mixes in clear to most drinks, making it a discreet addition. It also contains no added flavor.
  • Co-branding opportunities: The nature of the product makes for a perfect co-branding opportunity with any beverage manufacturer, healthcare sector, retailers, hospitality, travel and tourism industries.

The sachets will be available to consumers in four formats:

  1. Single serve sachets - 10 mg CBD available at select retail outlets at POS.
  2. Pack of 5 sachets - 10 mg CBD x 5.
  3. Box of 60 Sachets - 10 mg CBD x 60. Monthly supply.
  4. Bulk Orders for B2B - 10 mg CBD x >2000 sachets.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech, is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, Liviana™, and Handcrafted Delights™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "WUHN".

Publicly traded company (OTC Pink:WUHN)

Website: www.m2bio.co

E-mail:info@m2bio.co

Follow us on Twitter: https://twitter.com/m2bio

Follow us on Facebook: http://www.facebook.com/m2bio

Follow us on Instagram: https://www.instagram.com/m2bio.sciences

Forward-Looking Statements:

Safe Harbour Statement - In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./M2Bio Sciences, Inc.



View source version on accesswire.com:
https://www.accesswire.com/656450/M2Bio-Sciences-Food-and-Beverage-Launches-CBD-Sachets

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

QorusDocs Named LegalTech AI Platform of the Year and Ranked No. 1 Proposal Management Software17.11.2026 15:00:00 CET | Press release

BELLEVUE, WA / ACCESS Newswire / November 17, 2026 / QorusDocs, the pursuit intelligence platform trusted by dozens of Am Law 200 and Global 200 law firms, today announced it has been named LegalTech AI Platform of the Year in the seventh annual LegalTech Breakthrough Awards program and ranked the No. 1 proposal management solution by Info-Tech Research Group's SoftwareReviews, based on verified end-user reviews. The recognitions cap a year of rapid growth in legal for QorusDocs, which forecasts it will double its annual recurring revenue (ARR) from law firms in the next 12 months by adding more high-profile firms to its list of big law customers, which already includes DLA Piper, Baker McKenzie, Herbert Smith Freehills Kramer and Womble Bond Dickinson. Firms are moving AI beyond research and drafting and into business development, where a winning pitch depends on the best representative matters, strong attorney biographies and winning pitch strategies: knowledge general AI tools lack.

Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities17.11.2026 14:00:00 CET | Press release

CORTONA, IT / ACCESS Newswire / November 17, 2026 / Freezz Italia has been awarded a contract by the European Space Agency (ESA), as prime contractor leading a European industrial consortium, for the Consolidation Phase of the IRIS² Low-LEO Pre-Operational and De-Risk Activities, part of the ESA Programme Related to EU Secure Connectivity. The activity will further mature Friisat, Freezz's satellite system architecture conceived specifically for operation in Very Low Earth Orbit (VLEO) and designed for future broadband Direct-to-Device (D2D) connectivity within the 3GPP 5G/6G Non-Terrestrial Network (NTN) framework. Under this ESA contract, Freezz Italia will consolidate the mission and system architecture, adapting Friisat's existing commercial design to meet the requirements of an IRIS²-compatible solution, including future governmental broadband Direct-To-Device secure-connectivity services. The work will address the system and service concepts, architecture and interfaces, security

International Business Times UK Increases Programmatic Revenue by 30% with Opti Digital17.11.2026 11:00:00 CET | Press release

PARIS, FR / ACCESS Newswire / November 17, 2026 / Opti Digital, the leading AdTech company specialising in publisher revenue optimisation, today announced the results of its collaboration with International Business Times UK, an international digital news brand delivering business, markets, technology and current affairs coverage to a global readership. Operating in a fast-moving news environment, International Business Times UK continuously explores opportunities to increase the value of its digital audience while maintaining control over advertising quality and user experience. The publisher identified an opportunity to generate incremental revenue from its existing audience and inventory through a monetisation experience that could be tested progressively and scaled across a broader share of its inventory. "We were looking for ways to generate more value from our existing inventory, and the performance quickly demonstrated the potential of the new experience. It has become a meaning

OBI Pharma Signs Collaboration and License Agreement with Novartis16.11.2026 09:10:00 CET | Press release

TAIPEI, TW / ACCESS Newswire / November 16, 2026 / OBI Pharma, Inc. (4174.TWO) ("OBI") announced that it has entered into a Collaboration and License agreement with Novartis Pharma AG ("Novartis") to develop next generation Antibody-Drug-Conjugates (ADCs) with novel payloads, using OBI's suite of platform technologies. Under the terms of the agreement, Novartis will receive worldwide rights to OBI's related patents and know-how using its ADC platform technologies on an exclusive basis for selected, undisclosed Novartis payload classes. In parallel, under the collaboration OBI will evaluate novellinker approaches with the Novartis payloads. Novartis will further have the option to expand the agreement to include additional novel payload classes. This agreement marks an important milestone for OBI and underscores the value of its differentiated ADC technology platform. The agreement recognizes the potential of OBI's proprietary technologies, including GlycOBI®, EndoSymeOBI®, HYPrOBI®, an

Digi Power X Reports Q3 2026 Revenue Up 85% and AI Revenue Up Over 400% Compared to Q213.11.2026 13:30:00 CET | Press release

MIAMI, FL / ACCESS Newswire / November 13, 2026 / Digi Power X Inc. (Nasdaq:DGXX)(Cboe Canada:DGX) ("Digi Power X" or the "Company"), an AI data center infrastructure operator, today reported its financial and operating results for the third quarter ended September 30, 2026 (all amounts in U.S. dollars, unless otherwise indicated). The Company's quarterly report on Form 10-Q, which includes unaudited consolidated financial statements and management's discussion and analysis ("MD&A") for the quarter ended September 30, 2026, is being filed and made accessible under the Company's continuous disclosure profile on SEDAR+ at www.sedarplus.ca and will also be available on EDGAR at www.sec.gov/edgar. Third Quarter 2026 Highlights All amounts in U.S. dollars (millions) Revenue of $12.25 million, up 85% from the previously completed fiscal quarter and an increase of 50% compared to the quarter ended September 30, 2025; $119.6 million in cash, cash equivalents and digital currencies, $103.0 mill

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye